Kornimate/medical-research-clean huggingface dataset:
a singapore venaseal real world post-market evaluation study

Conditions: Varicose Veins; Venous Reflux; Chronic Venous Insufficiency

Summary: the study aims to assess the efficacy of venaseal™ closure system (vcs) for the treatment of lower extremity superficial truncal veins in a real-world clinical setting, in a multi-racial asian population in singapore.

the purpose of the asvs study is to investigate the performance of cyanoacrylate glue closure (cac) in a real-world post market evaluation setting in which multiple incompetent superficial saphenous truncal veins - namely (great saphenous vein (gsv), short saphenous vein (ssv), anterior accessory saphenous vein (aasv) - will be treated at the same setting, and compression stockings will not be used postoperatively. unlike previous studies, the inclusion criteria for this study will be liberalized, and veins up to 12mm in diameter will be treated. as such, asvs will be the first published prospective trial conducted in asia on a predominantly asian cohort of patients to report on the performance of cac for incompetent gsv and non-gsv trunks. this study specifically focuses on the initial technical outcomes, safety, anatomical occlusion and patient experience with cac applied with broader inclusion of patients than previous trials.

Eligibility criteria:
inclusion criteria: * age \> 21 years old and able to understand the requirements of the study and to provide informed consent * c2 - c5 symptomatic veins / chronic venous insufficiency * symptomatic primary gsv, ssv or aasv incompetence, with reflux \> 0.5 seconds on colour duplex, including one or more of the following symptoms: aching, throbbing, heaviness, fatigue, pruritus, night cramps, restlessness, generalized pain or discomfort, swelling * patients who had gsv, ssv or aasv diameters of 3mm to 12mm in the standing position exclusion criteria: * current dvt or history of dvt * recurrent varicose veins * pregnant patients * arterial disease (abpi\<0.8) * sepsis * patients who are unwilling to participate * inability or unwillingness to complete questionnaires * adverse reaction to sclerosant or cyanoacrylate * gsv, ssv or aasv severely tortuous * life expectancy \< 1 year * active treatment for malignancy other than non-melanoma skin cancer * current, regular use of systemic anticoagulation (e.g. warfarin, heparin) * daily use of narcotic analgesia or nsaids to control pain associated with venous disease

Keywords: endovenous ablation
nebulized tranexamic acid in sinus surgery

Conditions: Bleeding Nose

Summary: the results of several recent studies on endoscopic sinus surgery through topical administration of tranexamic acid are encouraging in terms of the efficacy of tranexamic acid for intraoperative bleeding and other pathological conditions.the purpose of this study is to analyze the efficacy of nebulized tranexamic acid to improve the surgeon and patient experiences of sinus surgery and know the effective and safe dose of nebulized tranexamic acid.

a written informed consent will be taken from the patients.the study involved adults of either sexes (age 18-65 years) of asa i-ii who will be listed for elective functional endoscopic sinus surgery (fess) under general anesthesia, with normal accepted coagulation profile and hematocrit value ≥30 %. excluded from the study patients with chronic renal failure, liver cirrhosis, bleeding disorders, current anticoagulant therapy, pregnancy or breastfeeding, impaired color vision, severe vascular ischemia, history of venous thrombosis, pulmonary embolism, long term treatment with acetylsalicylic acid or non-steroidal anti-inflammatory drugs not discontinued before surgery, a hemoglobin (hb) concentration \<10 mg/dl or allergy to txa. randomization: a random number sequence created by an internet website (http://www. random.org) will be used for patients' allocation. the random number sequence was retained in closed opaque envelopes released the day of the surgery by an independent physician not involved in the study. patients will be assigned randomly to three groups (30 subjects each); saline placebo (group s) and two different doses of preemptive nebulized tranexamic acid (group t1) and (group t2).to keep blinding, group s will receive 2 sessions of nebulization each by 5 ml saline. group t1 will receive one nebulization session 500 mg tranexamic acid (5 ml) and another one by 5 ml saline. group t2 will receive 2 nebulization sessions each by 500 mg tranexamic acid (each by 5 ml)

Eligibility criteria:
inclusion criteria: * either sexes (age 18-65 years) of asa i-ii who are listed for elective functional endoscopic sinus surgery (fess) under general anesthesia * normal accepted coagulation profile and hematocrit value ≥30 exclusion criteria: * chronic renal failure * liver cirrhosis * bleeding disorders * current anticoagulant therapy * pregnancy or breastfeeding * impaired color vision * severe vascular ischemia * history of venous thrombosis, pulmonary embolism * long term treatment with acetylsalicylic acid or non-steroidal anti-inflammatory drugs not discontinued before surgery * hemoglobin (hb) concentration \<10 mg/dl _allergy to txa.
rheumatoid arthritis through education and us study (raeus)

Conditions: Rheumatoid Arthritis

Summary: patients can potentially monitor disease activity of rheumatoid arthritis (ra) through self-assessed swollen joints (clinical synovitis)joint counts but reliability of joint swelling is poor. the objective is to evaluate the use of education by ultrasound feedback on the ability of patients to assess for clinical synovitis swollen joints in ra.

design: 6-month single centre randomized controlled trial. patients: established ra. intervention: education on self-assessment of joints that included initial brief patient training on tender (tjc) and swollen (sjc) joint counts, followed by us feedback every 3 months versus standard care without education. patient and physician independently performed 28-joint counts at each visit. outcome variables: (primary) percentage of patients with good agreement with physician derived swollen joints (prevalence-adjusted bias adjusted kappa, pabak\>0.6). other variables: agreement in sjc (bland and altman 95% limits of agreement), feasibility/patient satisfaction survey and disease activity score (das28) at 6 months.

Eligibility criteria:
inclusion criteria: * ra patients fulfilling acr1987 criteria * adults between age 21 and 80 years exclusion criteria: * pregnant * no mental health illness * fit to perform informed consent
safety and efficacy of transoral robotic thyroidectomy versus traditional open thyroidectomy for thyroid cancer

Conditions: Thyroid Cancers

Summary: in general, the utilization of the transoral vestibular approach in robotic surgery demonstrates efficacy comparable to that of traditional open surgery in the treatment of thyroid cancer. this method not only reduces the length of hospitalization for patients but also ensures superior cosmetic outcomes in the cervical region, thus achieving truly scarless aesthetics. the feasibility of transoral vestibular robotic thyroidectomy (tovrt) for tumors greater than 2 cm in diameter warrants further exploration in future studies; however, for tumors less than 2 cm in diameter, tovrt emerges as a safe, reliable, and practical alternative, poised to establish itself as an innovative surgical modality.


Eligibility criteria:
inclusion criteria: * age 18- 65 years old, both male and female * postoperative pathology was papillary thyroid carcinoma * clinical data integrity exclusion criteria: * postoperative pathology was benign * clinical data are incomplete
leukotriene antagonism in recruitment of cd49d expressing neutrophils in atopic subjects

Conditions: Nasal Allergy

Summary: the purpose of this study is to see if the recruitment of a certain cell type (the alpha 4 integrin (cd49d) expressing neutrophil) during a nasal allergen challenge can be inhibited by pretreatment with an fda approved leukotriene antagonist (montelukast).

subjects will be consented, undergo skin testing, medical history questionnaires, and randomized to either placebo or montelukast (10 mg). in one week, subjects return, undergo a blood draw, medical history questionnaires, nasal lavage, and nasal allergen challenge (followed by lavage in 6 hours). subjects will then cross-over to the other study drug. one week later subjects will undergo a blood draw, medical history questionnaires, lavage, allergen challenge, and repeat lavage (after 6 hours).

Eligibility criteria:
inclusion criteria: * 21 - 65 years of age, inclusive * a personal history of allergic rhinitis (hayfever) (by self-report) * at least one positive skin test to cat, dust mite mix, timothy grass, bermuda grass, bluegrass, or ragweed * ability to provide informed consent * willingness to undergo epicutaneous skin testing * willingness to undergo nasal lavages and nasal allergen challenges * willingness to undergo 2 peripheral blood draws (10 cc each) exclusion criteria: * use of systemic antihistamine in the past 5 days * use of intranasal corticosteroids or intranasal antihistamines currently or in the past 2 weeks * use of montelukast currently or in the past week * hypersensitivity or allergy to montelukast * inability to perform/undergo any study procedures * pregnancy (by subject report) or breastfeeding * confirmed or suspected immunodeficiency * persistent asthma, atopic dermatitis, or any other co-morbid disease except for allergic rhinitis * any symptoms of asthma in the past 2 weeks (shortness of breath, wheezing, and/or use of albuterol) * fever (temperature over 99f) currently or in the past 2 weeks * current or previous use of a biologic or investigational agent in the past 6 months * current or past suicidal thoughts/attempts

Keywords: allergen neutrophils allergy
effect of prp injection in releiving of symptoms of senile vaginitis

Conditions: Senile Vaginitis

Summary: 30 postmenopausal females with senile vaginitis will be enrolled with score of \<15 on the gloria bachman vaginal health index (vhi) intramucosal injections of prp will be adminstered and perform clinical evaluations at 0, 1, 3, and 6 months.

30 postmenopausal females with senile vaginitis will be enrolled with score of \<15 on the gloria bachman vaginal health index (vhi) intramucosal injections of prp will be adminstered and perform clinical evaluations at 0, 1, 3, and 6 months. the patients will be seen in ain shams university gynecological clinic and will not be paid either to receive the procedure or to complete the survey. all patients were fully informed of the innovative therapeutic and experimental nature of the localized prp injection and consented to the procedure. the materials and equipment included the following: 1. 5 cc syringes. 2. 27 gauge needles. 3. centrifuge with proprietary collection system. 4. calcium chloride 10% (for activation of prp). 5. and a topical anesthetic cream compounded with a base that prevents irritation and promotes absorption through the vaginal mucosa. active ingredients will be as follows: bupivicaine, lidocaine, and tetracaine with percent concentrations of 20/8/8 respectively. first, a topical anesthetic cream will be applied to the posterior vaginal wall. delaying the prp injection for 20 minutes after anesthetic application achieved complete or near complete analgesia for the procedure. peripheral blood will be drawn from the arm and centrifuged to yield 5 cc of prp. the regen® system concentrates 5ml of prp from 10 ml of whole blood using a gel separator. study interventions: after isolation of the prp, calcium chloride (0.5ml) was added to the 5 ml of prp isolate to activate the thrombin cascade, thereby causing degranulation of platelets, releasing growth factors and cytokines, and starting the transformation of the prp to platelet rich fibrin matrix (prfm) before the prfm became too gelatinous for passing through a needle (less than 10 minutes), two injections will be given through a 27-gauge needle in the posterior vaginal wall and perform clinical evaluations at 0, 1, 3, and 6 months.

Eligibility criteria:
inclusion criteria: * postmenopausal for at least 3 years. * vaginal health index \<15. * any parity. exclusion criteria: * women with vaginal infection. * women taking estrogen therapy for senile vaginitis. * any patient with medical disorder especially diabetes mellitus. * previous vaginal surgery as fistula repair or classical repair. * vaginal prolapse * any patient taking chemo or radiotherapy.
study of the efficacy of local analgesia as an adjunct to general anesthesia in thyroidectomy and parathyroidectomy

Conditions: Thyroid Neoplasms; Goiter, Nodular; Thyroid Nodule; Graves' Disease; Hyperparathyroidism

Summary: we aim to study the effect of local anesthetic when used in conjunction with general anesthesia during thyroidectomy or parathyroidectomy. we hypothesize there is equivalent pain control between bilateral superficial cervical plexus block and local wound infiltration when used in conjunction with a general anesthetic.


Eligibility criteria:
inclusion criteria: * patient ≥ 18 years old * surgical indication for parathyroidectomy or thyroidectomy exclusion criteria: * patients \< 18 years old * patient with history of chronic opioid use * patient with chronic pain syndromes * patient with allergy to marcaine
interaction between benralizumab and basophils in eosinophilic asthma

Conditions: Asthma; Eosinophilic

Summary: in this study, investigators want to evaluation of the impact of benralizumab (fasenra®, astra zeneca) on different cell populations, including basophils and innate lymphoid cells, and several biomarkers, such as mirnas, cadena α dek receptor pra la interleukin % (il5rα) and soluble il5rα in patients with severe eosinophilic asthma. for this, basophil and innate cells type 2 (ilc2) populations will be monitored in different point-time of treatment: 8 week (v1), 6 months (v2) and 1 year (v3) in blood and sputum samples. also, follow-up il5rα expression on a cell surface of eosinophils, basophils and ilc2 from peripheral blood and sputum of patients treated with or or without benralizumab. determination of il5rα levels will be performed by flow cytometry

for this: 1. investigators will monitor basophil mirnas changes with benralizumab analyzing mirnas profile of isolated basophil before and after benralizumab treatment. 2. also, in vitro characterization of benralizumab effects on functionality of human basophils (isolated from allergic asthmatic patients) and human cell line ku812, measuring apoptosis, activation, degranulation and histamine release will be performed.

Eligibility criteria:
inclusion criteria: * .it is mandatory that all patients can comprehend the study requirements and provide informed consent for their participation in mega. group a: * adult people (≥ 18 and ≤ 80 years old) with eosinophilic severe asthma requiring high-dose inhaled corticosteroids plus long-acting beta agonists (with or without long-acting muscarinic antagonist or montelukast or oral corticosteroids) * benralizumab treatment approved. group b: .patients with allergic asthma (prick test or rast positive). exclusion criteria: * patients with continuous ocs treatment * patients with immunosuppressive drugs * patients with primary or secondary immune deficiency, * patients with chronic or/and concomitant disease, presence of severe systemic disease or cancer, * patients with possible infestation by parasites. * patients with other acute or chronic active lung disorders patients with significant psychiatric disorders * patients with biological treatment will be excludes for group b

Keywords: asthma basophils anti-receptor de interleukin 5 micrornas benralizumab
pulsed af post-approval study

Conditions: Atrial Fibrillation

Summary: pulsed af pas is a prospective, global, multi-center, non-randomized, observational trial. subjects will be treated with the pulseselect™ pfa system and followed through 36 months.

pulseselect is a prospective, global, multi-center, non-randomized, observational trial. subjects will be treated with the pulseselect™ pfa system and followed through 36 months. study visits will occur at 3, 6, 12, 24, and 36 months post-ablation, including required 24-hour holter monitoring at 6, 12, 24, and 36 month visits. the pulseselect™ pfa system used in this study is market approved and the ablation procedure will be performed according to hospital standard of care.

Eligibility criteria:
inclusion criteria: * a diagnosis of recurrent symptomatic paroxysmal af or persistent af * failure or intolerance of at least one class i or iii antiarrhythmic drug * patient is ≥ 18 years of age * planned pulmonary vein isolation procedure with the commercially available pulseselect™ pfa system * willing and able to comply with study requirements and give informed consent (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements exclusion criteria: * long-standing persistent af (continuous af sustained \>12 months) * prior left atrial ablation or left atrial surgical procedure * patient with life expectancy \< 36 months * presence of a permanent pacemaker, biventricular pacemaker, loop recorder/insertable cardiac monitor (icm), or any type of implantable cardiac defibrillator (with or without biventricular pacing function) * current or anticipated participation in any other clinical trial of a drug, device, or biologic not approved by the global study manager
double blind randomized, monocentric, cross-over, placebo-controlled study to evaluate the effect of morphine and naloxone on motivation (mbbanalgesic)

Conditions: Healthy

Summary: the aim of the current study is to examine the role of the opioïd system on the cognitive parameters of motivation. they are embedded in a conceptual framework of motivation that merges decision-making and reinforcement learning theories. every action is conceived as path from one state to another. the different states are associated to different values (positive for rewards and negative for punishments), and the different actions to different costs (risk, effort and delay). the tasks are designed such that the sensitivity to the state and action parameters can be inferred by fitting computational models.the primary objective is to characterize the effect of morphine 0,05mg/kg and naloxone 10mg on cost accumulation slope, assessed in an effort management task, in which participants are asked to squeeze a hand grip during 30 seconds at varying level of effort in order to win monetary payoff. secondary objectives are to characterize the effect of morphine 0,05mg/kg and naloxone 10mg on other cognitive parameters of motivation (assessed with a motivational battery that includes rating, choice and learning tasks).


Eligibility criteria:
inclusion criteria: * man or woman, age ≥ 18 and \< 50 * weight between 50 kg and 90 kg. * no contraindication to effort * no evolutive pathology that could interfere with the current study signed consent * medical insurance ("sécurité sociale") exclusion criteria: * age \ 50 * smokers * person under curatorship, or guardianship, or with civil rights deprivation * history of neurologic or psychiatric pathology * chronic or actual consumption of alcohol, or psychotropic drugs * pregnancy, breastfeeding * woman of childbearing potential without effective contraception * liver failure * severe cardiovascular disorders * severe cerebrovascular discorders * morphine (or naloxone) hypersensitivity/addiction * treatment contraindicated: morphine dérivatives, neuroleptics, barbiturate, benzodiazepine, anxiolytics, hypnotics, antidepressant, antihistamine, antihypertensives, beta blocker, baclofen, thalidomide * enzyme inducers, (rifampicine, ...) * treatment that can interfere with the performance of the subject: beta2 adrenergic agonists, analgesics, corticosteroïds, anti-inflammatory drugs, ...

Keywords: volunteers
intensive insulin therapy and acute kidney injury. analysis using rifle criteria.

Conditions: Kidney; Injury

Summary: the purpose of this study is to determine if intensive insulin therapy really reduces the incidence of acute kidney injury in critically ill patients, using for analysis the rifle criteria for definition of aki.


Eligibility criteria:
inclusion criteria: * we included 337 adult patients, non pregnant, admitted from july 1, 2004 to december 31, 2006, to a 20-bed multidisciplinary icu of a general hospital and to an 11-bed trauma center icu that had at least two blood glucose levels above 150 mg/dl from three measurements obtained in the first 12 hours after admission. exclusion criteria: * pregnant patients

Keywords: intensive insulin therapy carbohydrate restrictive strategy rifle criteria acute kidney injury critically ill patients acute
type 1 diabetes rest for metabolic health

Conditions: Type 1 Diabetes (T1D); Sleep Health

Summary: research has shown a link between poor sleep health and late circadian timing with cardiometabolic health in adolescents with type 1 diabetes (t1d). cardiovascular disease (cvd) is the leading cause of morbidity and mortality in t1d, which begins as early as adolescence, and current therapies are limited. therefore, this study plans to investigate whether cardiometabolic health can be improved with increased sleep duration and advanced circadian timing in adolescents with t1d with habitually insufficient sleep. to answer this question, investigators will study adolescents with t1d who get \&lt;7h sleep on school nights and measure changes in insulin sensitivity, glycemic control, and vascular function after one month of a sleep and circadian intervention (1+ hour longer time in bed each night plus evening melatonin and morning light therapy) compared to one month of typical sleep (usual school schedule).


Eligibility criteria:
inclusion criteria: * high school students between the ages of 14-19 years; * diagnosed with t1d for ≥1 year; * using an insulin pump or other automated insulin delivery system; * have typically insufficient sleep, defined by ≤ 7 h per night on school days (assessed by actigraphy); * with or at risk for obesity based on either above-average weight (bmi ≥50th percentile) or parental history of obesity (bmi ≥ 30 kg/m2); * tanner stage 4 or 5, based on breast development for girls and testicular size for boys. exclusion criteria: * prior diagnosis of a sleep disorder (e.g., insomnia, obstructive sleep apnea) or an elevated screening score on the osa subscale of the sleep disorders inventory for students-adolescents measure * regular use of medications affecting sleep (e.g., stimulants, atypical antipsychotics, melatonin or other sleep aids); * regular use of medications affecting ir (systemic steroids, adjunctive diabetes medications); * hba1c ≥12%; * severe illness or dka within 60 days; * iq\&lt;70 or severe mental illness impacting sleep or ability to participate in the study; * night-shift employment or other obligations that would preclude adherence to the intervention.